Anemia of Chronic Kidney Disease
Conditions
Keywords
Chronic Kidney Disease, Hemodialysis, Erythropoiesis-Stimulating Agent, Open-label, Vadadustat
Brief summary
This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the treatment of anemia in in-center hemodialysis participants with end-stage kidney disease (ESKD). A subset of sites will participate in a red blood cell (RBC) sub-study where changes in the phenotype of RBCs in response to vadadustat treatment relative to methoxy polyethylene glycol-epoetin beta treatment in DD-CKD participants with anemia will be assessed. A separate informed consent form (ICF) will be signed by these participants who opt to be in the RBC sub-study. Of the 350 participants in the main study, approximately 28 participants will also be enrolled into the RBC sub-study. The total duration of the study is approximately 35 Weeks including screening and follow-up.
Interventions
Administered by intra-venous (IV) infusion.
DRUGVadadustat
300mg, oral tablets
Sponsors
Akebia Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult participants ≥18 years of age. * Receiving outpatient in-center hemodialysis for ESKD at least three times a week. * Currently prescribed or meets criteria for ESA based on approved facility policy. * Hb \> 8 grams per deciliter (g/dl). * Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20%. * Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure. * For selected sites, individuals who opt to participate in the RBC sub-study must meet the following inclusion criteria: * Currently prescribed or will be prescribed methoxy polyethylene glycol-epoetin beta. * Hb \<11.5 g/dL
Exclusion criteria
* Contraindication to receive vadadustat per United States prescribing information (USPI) as determined by the treating health care provider. * Concomitant use of any hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI). * Known cirrhosis or active, acute liver disease. * Unable to comply with study requirements or compliance with attending dialysis treatments as prescribed, or in the opinion of the treating physician or Investigator, not clinically stable to participate in the study. * Pregnant at the time of consent (per participant self-report). * Any other reason, which in the opinion of the Investigator, would make the participants unsuitable for participation in the study. * For selected sites, individuals who opt to participate in the RBC sub-study must also not meet the following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in hemoglobin (Hb) | Baseline and the mean of Week 20 to 24 |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants reporting treatment-emergent serious adverse events (TESAEs) | Up to 29 Weeks |
| Proportion of participants with mean Hb levels within target range | Week 16 to Week 24 |
| Proportion of participants receiving RBC transfusions | Up to 29 Weeks |
Countries
United States
Outcome results
None listed